Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Kairos Pharma, Ltd.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered | Proposed Maximum Offering Price Per Share | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||||||||||||||
| Equity | Kairos Pharma, Ltd. 2023 Equity Incentive Plan – Common Stock, $0.001 par value per share | 457(h) |
1,650,000 shares | (1)(2) | $ | 1.69 | (3) | $ | 2,788,500 | (3) | 0.0001476 | $ | 411.59 | |||||||||||||
| Total Offering Amounts | $ | 2,788,500 | $ | 411.59 | ||||||||||||||||||||||
| Total Fee Offsets | - | - | - | |||||||||||||||||||||||
| Net Fee Due | $ | 411.59 | ||||||||||||||||||||||||
| (1) | Represents the maximum number of shares of common stock, par value $0.001 per share (“Common Stock”), of Kairos Pharma, Ltd. (the “Registrant”) issuable pursuant to the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the “Plan”) being registered herein. | |
| (2) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Act”) this Registration Statement also covers such additional shares of Common Stock, as may issue to prevent dilution from stock splits, stock dividends and similar transactions. | |
| (3) | Estimated solely for the purposes of determining the amount of the registration fee, pursuant to Rule 457(h) under the Securities Act, based upon the average high and low price of the Common Stock as reported on the Nasdaq Capital Market on September 26, 2024. |
